GSK-444563/013



A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa
Rotavirus Vaccine
444563/013
NCT00383903
Infections, Rotavirus
Phase 2
 
An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014